Eli Lilly Operating Expenses 2010-2022 | LLY

Eli Lilly annual/quarterly operating expenses history and growth rate from 2010 to 2022. Operating expenses can be defined as the sum of all operating expenses for the given industry.
  • Eli Lilly operating expenses for the quarter ending June 30, 2022 were $5.278B, a 1.1% decline year-over-year.
  • Eli Lilly operating expenses for the twelve months ending June 30, 2022 were $21.658B, a 3.64% increase year-over-year.
  • Eli Lilly annual operating expenses for 2021 were $21.961B, a 18.83% increase from 2020.
  • Eli Lilly annual operating expenses for 2020 were $18.482B, a 6.55% increase from 2019.
  • Eli Lilly annual operating expenses for 2019 were $17.345B, a 3.42% decline from 2018.
Eli Lilly Annual Operating Expenses
(Millions of US $)
2021 $21,961
2020 $18,482
2019 $17,345
2018 $17,959
2017 $17,971
2016 $17,961
2015 $17,269
2014 $16,956
2013 $17,743
2012 $17,869
2011 $18,758
2010 $16,546
2009 $16,249
Eli Lilly Quarterly Operating Expenses
(Millions of US $)
2022-06-30 $5,278
2022-03-31 $5,406
2021-12-31 $6,083
2021-09-30 $4,892
2021-06-30 $5,337
2021-03-31 $5,650
2020-12-31 $5,448
2020-09-30 $4,462
2020-06-30 $4,303
2020-03-31 $4,269
2019-12-31 $4,714
2019-09-30 $4,046
2019-06-30 $4,138
2019-03-31 $4,447
2018-12-31 $4,737
2018-09-30 $3,964
2018-06-30 $5,590
2018-03-31 $3,668
2017-12-31 $2,985
2017-09-30 $5,116
2017-06-30 $4,624
2017-03-31 $5,245
2016-12-31 $5,082
2016-09-30 $4,248
2016-06-30 $4,482
2016-03-31 $4,149
2015-12-31 $5,048
2015-09-30 $3,998
2015-06-30 $4,103
2015-03-31 $4,120
2014-12-31 $4,813
2014-09-30 $4,277
2014-06-30 $4,049
2014-03-31 $3,817
2013-12-31 $4,930
2013-09-30 $4,228
2013-06-30 $4,427
2013-03-31 $4,158
2012-12-31 $4,946
2012-09-30 $4,304
2012-06-30 $4,399
2012-03-31 $4,221
2011-12-31 $5,054
2011-09-30 $4,562
2011-06-30 $4,664
2011-03-31 $4,478
2010-12-31 $4,851
2010-09-30 $3,902
2010-06-30 $3,967
2010-03-31 $3,826
2009-12-31 $5,384
2009-09-30 $3,876
2009-06-30 $3,696
2009-03-31 $3,293
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.922B $28.318B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84
Novartis AG (NVS) Switzerland $192.828B 14.22